Accueil>>Signaling Pathways>> Cell Cycle/Checkpoint>> PAK>>AZ13705339 hemihydrate

AZ13705339 hemihydrate

Catalog No.GC66036

L'hémihydrate d'AZ13705339 est un inhibiteur de PAK1 très puissant et sélectif avec des IC50 de 0,33 nM et 59 nM pour PAK1 et pPAK1, respectivement. L'hémihydrate AZ13705339 a des affinités de liaison avec PAK1 et PAK2, avec des Kd de 0,28 nM et 0,32 nM, respectivement. L'hémihydrate AZ13705339 peut être utilisé dans la recherche sur les cancers.

Products are for research use only. Not for human use. We do not sell to patients.

AZ13705339 hemihydrate Chemical Structure

Taille Prix Stock Qté
10mg
225,00 $US
En stock
25mg
495,00 $US
En stock
50mg
765,00 $US
En stock
100mg
1 215,00 $US
En stock

Tel:(909) 407-4943 Email: sales@glpbio.com

Avis des clients

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents

AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers[1].

AZ13705339 (1 μM) hemihydrate inhibits αIgM-controlled adhesion and not PMA-induced adhesion in Namalwa cells[2].
AZ13705339 (300 nM, 30 min) prevents Siglec-8 engagement-induced eosinophil death[3].

AZ13705339 hemihydrate (100 mg/kg, P.O.) has moderate clearance and oral Cmax of 7.7 μM in rats[1].

Avis

Review for AZ13705339 hemihydrate

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for AZ13705339 hemihydrate

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.